Abstract
T Cell Immunoprofiling of Patients with Relapsed and/or Refractory Myeloma Who Receive Daratumumab Monotherapy: Longitudinal Analysis during 7 Cycle Follow-up of the Rebuild Phase 2 Study
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have